埃及经典霍奇金淋巴瘤患者中 CD68+ 巨噬细胞的作用。
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt.
机构信息
Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Medical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
出版信息
Diagn Pathol. 2020 Feb 4;15(1):10. doi: 10.1186/s13000-019-0912-3.
BACKGROUND
CD68+ tumor-associated macrophages (TAM) play an important role in the progression of classical Hodgkin lymphoma (cHL). We assessed the role of CD20 and CD68 + TAM in a cohort of cHL patients from Egypt and correlated the number of CD68 + cells with patients' characteristics, response to treatment, overall and progression free survival rates (OS & PFS).
METHODS
CD20 expression and CD68 + TAM numbers were assessed in representative tumor tissues obtained from 81 cHL patients using flowcytometry (FCM), immunohistochemistry (IHC), and Rt-PCR techniques.
RESULTS
The expression levels of CD68 protein by IHC was high in 27 (33.3%), moderate in 15 (18.5%), low in 15 (18.5%), and negative in 24 (29.6%) patients (p = 0.13). CD68-mRNA expression was high in 43/81(53.1%), and low in 38(46.9%) patients (p = 0.6). The number of CD68 + TAM (by FCM) was low (< 20 cells) in 42/81 (51.9%), and high (≥20 cells) in 39/81 (48.1%) patients (p = 0.74). CD68 expression (by FCM, IHC& Rt-PCR) associated significantly with poor response to treatment, decreased CD20 expression, reduced OS and PFS rates (p < 0.001 for all). CD68 expression (by Rt-PCR only) associated significantly with advanced disease stage (p = 0.04). The age of the patients, high CD20 expression & high CD68+ macrophage number were independent prognostic factors for OS (p= 0.02, p = 0.008 & p = 0.009; respectively). However, the age of the patient, high CD20, and high CD68+ macrophage expression (by FCM&IHC) were independent prognostic factors for DFS (p. = 0.004, p. = 0.01, p. = 0.007 and p. = 0.01; respectively).
CONCLUSION
CD68 + TAM expression (by Rt-PCR, FCM and/or IHC) can identify patients with poor response to treatment and reduced survival rates (OS& PFS). Assessment of CD68 + positive macrophages by FCM is superior to other methods (Rt-PCR and IHC) as a prognostic factor for DFS and OS rates.
背景
CD68+肿瘤相关巨噬细胞（TAM）在经典霍奇金淋巴瘤（cHL）的进展中起着重要作用。我们评估了 CD20 和 CD68+TAM 在来自埃及的 cHL 患者队列中的作用，并将 CD68+细胞数量与患者特征、对治疗的反应、总生存率和无进展生存率（OS 和 PFS）相关联。
方法
使用流式细胞术（FCM）、免疫组织化学（IHC）和 RT-PCR 技术评估 81 例 cHL 患者代表性肿瘤组织中的 CD20 表达和 CD68+TAM 数量。
结果
81 例患者中，CD68 蛋白的 IHC 表达水平高 27 例（33.3%）、中 15 例（18.5%）、低 15 例（18.5%）、阴性 24 例（29.6%）（p=0.13）。CD68-mRNA 表达高 43/81（53.1%），低 38/81（46.9%）（p=0.6）。CD68+TAM（通过 FCM）的数量低（<20 个细胞）42/81（51.9%），高（≥20 个细胞）39/81（48.1%）（p=0.74）。CD68 表达（通过 FCM、IHC 和 RT-PCR）与治疗反应不良、CD20 表达降低、OS 和 PFS 率降低显著相关（所有 p<0.001）。CD68 表达（仅通过 RT-PCR）与晚期疾病阶段显著相关（p=0.04）。患者年龄、高 CD20 表达和高 CD68+巨噬细胞数量是 OS 的独立预后因素（p=0.02、p=0.008 和 p=0.009；分别）。然而，患者年龄、高 CD20 和高 CD68+巨噬细胞表达（通过 FCM 和 IHC）是 DFS 的独立预后因素（p. = 0.004、p. = 0.01、p. = 0.007 和 p. = 0.01；分别）。
结论
CD68+TAM 表达（通过 RT-PCR、FCM 和/或 IHC）可以识别治疗反应不良和生存率降低（OS 和 PFS）的患者。FCM 评估 CD68+阳性巨噬细胞作为 DFS 和 OS 率的预后因素优于其他方法（RT-PCR 和 IHC）。
Zotero 插件